fda semaglutide compounding Troubling Findings in Study of GLP-1 Compounders FDA issues warning about some

ATF6-mediated signaling contributes to PARP inhibitor resistance in ovarian cancer

The result can be a week of feeling absolutely terrible

A paper was published in the most impactful medical journal in the world, The New England Journal of Medicine , where 412 patients with HIV were randomized to receive either 2 mg of tesamorelin or placebo for 26 weeks

FDA approved a new higher dose of Wegovy 7.2 mg semaglutide injection in 2026 for weight loss and long-term weight maintenance in certain adult patients, reinforcing semaglutide's role in higher-intensity obesity treatment

Myth: Ozempic is a quick fix for weight loss First, Ozempic isn't approved for weight loss